{
    "organizations": [],
    "uuid": "5940eb9ab5d2c582372f5e75989ce32dcc7ed8de",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fibrogen-reports-q1-loss-per-share/brief-fibrogen-reports-q1-loss-per-share-0-50-idUSASC0A12P",
    "ord_in_thread": 0,
    "title": "BRIEF-FibroGen Reports Q1 Loss Per Share $0.50",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - FibroGen Inc:\n* Q1 LOSS PER SHARE $0.50 * Q1 EARNINGS PER SHARE VIEW $-0.51 â€” THOMSON REUTERS I/B/E/S\n* ROXADUSTAT U.S. PHASE 3 CLINICAL STUDIES ON TRACK TO READOUT IN Q4 2018\n* QTRLY TOTAL REVENUE $31.9 MILLION VERSUS $29.4 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:17:00.000+03:00",
    "crawled": "2018-05-10T17:49:41.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "fibrogen",
        "inc",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "roxadustat",
        "phase",
        "clinical",
        "study",
        "track",
        "readout",
        "q4",
        "qtrly",
        "total",
        "revenue",
        "million",
        "versus",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}